×
Pyxis Oncology Operating Expenses 2021-2024 | PYXS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Pyxis Oncology operating expenses from 2021 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
Pyxis Oncology Operating Expenses 2021-2024 | PYXS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Pyxis Oncology operating expenses from 2021 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$89B
Takeda Pharmaceutical (TAK)
$47.2B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$22.1B
Summit Therapeutics (SMMT)
$17.8B
Sandoz Group AG (SDZNY)
$17.6B
United Therapeutics (UTHR)
$15.2B
Shionogi (SGIOY)
$13.1B
Neurocrine Biosciences (NBIX)
$12.1B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Corcept Therapeutics (CORT)
$4.4B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Dyne Therapeutics (DYN)
$3.4B
PTC Therapeutics (PTCT)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B